Kenvue’s Dividend Appeal Now Hinges on Kimberly-Clark Deal

Kenvue’s appeal is unusually straightforward: a portfolio of household health brands, a dividend yield near 4.7%, and a 64-year record of annual payout increases. The complication is that investors may soon own Kimberly-Clark instead.

The consumer-health company, spun out of Johnson & Johnson in 2023, has built its case around products people continue buying through economic slowdowns. Tylenol, Listerine, Band-Aid, Neutrogena and Zyrtec do not depend on a consumer upgrading to a new phone or booking a vacation. That defensive demand helped Kenvue produce $3.95 billion in second-quarter sales, up 3% from a year earlier, while diluted earnings per share rose 9% to 24 cents. Kenvue reported its third consecutive quarter of net and organic sales growth.

The dividend is the main attraction. At Kenvue’s recent share price near $17.92, the yield is materially above the S&P 500’s typical payout and comes with a Dividend King pedigree inherited from the consumer-health business’s years inside Johnson & Johnson.

But Kenvue is no longer a simple standalone income stock. Kimberly-Clark agreed to acquire it in a transaction valued at roughly $48.7 billion, with Kenvue shareholders set to receive $3.50 in cash plus 0.14625 shares of Kimberly-Clark for each Kenvue share. Both companies’ shareholders approved the deal in January, though foreign regulatory clearances and other closing conditions remain.

That structure creates a different dividend proposition. Kenvue has suspended forward guidance while the transaction proceeds, and its payout policy after closing will effectively become Kimberly-Clark’s responsibility. Kimberly-Clark is also a Dividend King, with a longer-established consumer-products base and a yield recently above 5%, but the combined company will carry integration costs and substantial execution demands.

Regulators have already required remedies in at least one market. New Zealand cleared the acquisition in August subject to divestiture of Kenvue’s feminine-hygiene business, while the European Union opened a formal review process in September.

For income investors, KVUE therefore offers two routes to value: a dependable payout while the deal remains pending and potential ownership of a higher-yielding, broader consumer-staples company after closing. The trade-off is that dividend certainty now depends partly on a merger that has not yet crossed the finish line.